Arcus Biosciences, Inc.
NYSE:RCUSBiotechnology
-$0.09 today
- Market cap
- $2.27B
- Beta
- 0.84
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$2.94
Volume 1.97M
Average 1.17M
RCUS Sales of Investments
Cash received from selling or redeeming investments.
Arcus Biosciences, Inc.NYSE: RCUS
Sales of Investments · Q2 FY2026 · quarter ended Jun 2026
Sales of investments declines year over year
Q2 FY2026 sales of investments of $234M fell 21.5% year over year, behind the -17.3% change in trailing-twelve-month sales of investments. Sequentially, it fell 11.4% from the prior quarter. Over 3 fiscal years it compounded at +11.0% a year.
Context
- Sales of investments amounted to 463.2% of revenue in FY2025, up 89.1 pp from a year earlier.
- Sales of investments increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -21.5% toward the trailing-twelve-month pace of -17.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 1.14B USD
- Year-over-year change
- +18.5%
- 4-year CAGR
- +11.5%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.14B | +18.5% |
| FY2024 | 2024-12-31 | 965M | -4.1% |
| FY2023 | 2023-12-31 | 1.01B | +20.2% |
| FY2022 | 2022-12-31 | 837M | +12.9% |
| FY2021 | 2021-12-31 | 741.08M | — |
Sales of Investments vs competitors
How RCUS compares with its peers on the latest reported figures
- RCUS's LTM Jun 2026 sales of investments of $958M is the 2nd largest of the 9 companies compared; the peer median is $465.55M.
- Its year-over-year change of -17.3% is the lowest of 7, against a peer median of +14.8%.
- Sales of investments amounts to 818.8% of revenue for RCUS, versus a peer median of 524.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.04B | +40.3% | -3.4% | 1567.4% | |
| LTM Jun 2026 | $958M | -17.3% | +11.0% | 818.8% | |
| LTM Jun 2026 | $818.71M | +17.6% | -11.0% | 524.7% | |
| LTM Jun 2026 | $799.11M | -8.5% | -10.7% | 22172.9% | |
| LTM Jun 2026 | $556.71M | -1.6% | +70.7% | 782.7% | |
| LTM Sep 2026 | $374.39M | +1501.0% | — | 205.1% | |
| LTM Jun 2026 | $337.64M | +12.1% | +68.9% | — | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding RCUS) | $465.55M | +14.8% | -3.4% | 524.7% | |
Competitors are the stored peer set for RCUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 52.83M | (267M) | (307M) | (283M) | (353M) |
| Depreciation & Amortization | 4M | 6M | 8M | 10M | 10M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 55M | 65M | 73M | 76M | 60M |
| Change in Working Capital | (375.62M) | 623M | (71M) | 22M | (194M) |
| Accounts Receivables | (17.05M) | 704M | 15M | 28M | 9M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.77M) | 8M | (1M) | 3M | 24M |
| Other Working Capital | (353.8M) | (89M) | (85M) | (9M) | (227M) |
| Other Non-Cash Items | 7.62M | 11M | (9M) | 5M | (5M) |
| Operating Cash Flow | (256.17M) | 438M | (306M) | (170M) | (482M) |
| Capital Expenditures | (26.08M) | (6M) | (24M) | (6M) | (2M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (718.87M) | (1.24B) | (788M) | (1.04B) | (1.08B) |
| Sales of Investments | 741.08M | 837M | 1.01B | 965M | 1.14B |
| Other Investing Activities | 0 | (3M) | 0 | 0 | 0 |
| Investing Cash Flow | (3.87M) | (413M) | 194M | (84M) | 66M |
| Debt Repayment | 5M | 0 | 0 | 47M | 49M |
| Common Stock Issued | 232.35M | 23M | 25M | 228M | 439M |
| Common Stock Repurchased | (6K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 10M | 8M | 2M | 0 |
| Financing Cash Flow | 237.34M | 33M | 33M | 277M | 488M |
| Effect of Forex Changes | (2.8M) | 0 | 0 | 0 | 0 |
| Net Change in Cash | (25.5M) | 58M | (79M) | 23M | 72M |
| Free Cash Flow | (282.25M) | 432M | (330M) | (176M) | (484M) |
Arcus Biosciences, Inc.
NYSE:RCUS
Intrinsic Alpha fair value
Locked
Current Price
$15.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.